Related Experiment Videos
Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy
1Department of Obstetrics and Gynecology, Northwestern University Medical Center, Chicago, Illinois, USA.
Objective:
Our purpose was to evaluate the efficacy and toxicity of single-agent chemotherapy and to identify risk factors associated with chemotherapy resistance in the treatment of low-risk metastatic gestational trophoblastic tumors.
Study Design:
We reviewed the records of all patients with gestational trophoblastic tumors treated with single-agent chemotherapy at the John I. Brewer Trophoblastic Disease Center of Northwestern University between 1962 and 1992. A total of 92 patients with low-risk metastatic gestational trophoblastic tumors by National Cancer Institute criteria were identified. Patients received methotrexate (n = 61), actinomycin D (n = 4), alternating methotrexate and actinomycin D (n = 5), or hysterectomy with methotrexate (n = 20) or actinomycin D (n = 2).
Results:
All 92 patients with low-risk metastatic gestational trophoblastic tumors were cured. Primary remission was achieved with initial single-agent therapy in 62 patients (67.4%). A second sequential single agent was used because of drug resistance in 20 patients (21.7%) or drug toxicity in 10 patients (10.9%). Only one patient (1%) needed multiagent chemotherapy to be cured. Adjuvant hysterectomy was performed in 22 patients (23.9%). Surgery was not required to remove resistant tumor foci. Chemotherapy toxicity, most commonly stomatitis, occurred in 36 patients (39.1%), but none of these effects was life threatening. Large vaginal metastasis was the only identifiable factor significantly associated with failure of initial single-agent chemotherapy (p = 0.03).
Conclusion:
In this large series of patients with low-risk metastatic gestational trophoblastic tumors, sequential single-agent chemotherapy with methotrexate and actinomycin D provided safe and extremely effective treatment.
Insights
Single-agent chemotherapy, including methotrexate and actinomycin D, effectively cures low-risk metastatic gestational trophoblastic tumors. Large vaginal metastasis was the only risk factor identified for chemotherapy resistance.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Chemotherapy Research
Background:
- Gestational trophoblastic tumors (GTT) are a group of pregnancy-related tumors requiring effective treatment strategies.
- Low-risk metastatic GTT necessitates evaluation of chemotherapy efficacy and toxicity to optimize patient outcomes.
- Identifying factors associated with chemotherapy resistance is crucial for refining treatment protocols.
Purpose of the Study:
- To assess the effectiveness and safety of single-agent chemotherapy for low-risk metastatic GTT.
- To determine risk factors linked to chemotherapy resistance in this patient population.
Main Methods:
- Retrospective review of 92 patients with low-risk metastatic GTT treated between 1962 and 1992.
- Patients received single-agent chemotherapy: methotrexate, actinomycin D, or sequential combinations.
- Analysis included cure rates, drug resistance, toxicity, and associated risk factors.
Main Results:
- All 92 patients achieved a cure with single-agent chemotherapy.
- Initial remission occurred in 67.4% of patients; 21.7% required a second agent due to resistance.
- Chemotherapy toxicity was generally mild (39.1%), with large vaginal metastasis being the sole significant predictor of initial treatment failure (p=0.03).
Conclusions:
- Sequential single-agent chemotherapy using methotrexate and actinomycin D is a safe and highly effective treatment for low-risk metastatic GTT.
- The treatment regimen demonstrated excellent cure rates with manageable toxicity.
- Large vaginal metastasis is a key factor to consider in treatment planning for GTT.